Newsroom | 19693 results

LA JOLLA, Calif.--(BUSINESS WIRE)--Arialys Announces U.S. FDA Fast Track Designation for ART5803, the First Precision Therapeutic Candidate in Development for the Treatment of ANRE...

LOS ANGELES--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its CEO, Rob Fried, will participate in a virtual fireside chat hosted by KCSA Strategic Communications on Wednesday, July 15, 2026, at 8 am PDT. During the discussion, Mr. Fried will discuss the recently launched pharmaceutical program for rare genetic diseases and aging-related disorders, the C...

SAN JOSE, Calif.--(BUSINESS WIRE)--President & CEO of Takara Bio USA Carol Lou announces she is retiring after 20 years of service, with Andrew Farmer as her successor....

DALLAS & FORT WORTH, Texas--(BUSINESS WIRE)--Neo7Bioscience Announces Precision Signal Interception for Pancreatic Cancer Treatment Beyond Conventional RAS Pathway Suppression...

ST. LOUIS--(BUSINESS WIRE)--Confluence Genetics today announced the launch of Cas-CLEAR™, Collaterally Enhanced Activated Ribonuclease, a new CRISPR technology platform for the treatment of cancers carrying defined genetic signatures, with lead programs in development for hepatocellular carcinoma (HCC). Unlike gene editing CRISPR systems that cut and modify DNA at a single site, Cas-CLEAR uses Cas12a2 nucleases to recognize cancer-specific genetic signatures and trigger broad collateral cleavag...

SAN FRANCISCO--(BUSINESS WIRE)--Amprion, a global leader advancing diagnosis of neurodegenerative disorders through seed amplification testing, and Modality.AI, a leader in AI-enabled multimodal clinical assessments, today announced a collaboration to explore how molecular biomarkers and objective digital assessments can be combined to improve the characterization of central nervous system (CNS) disorders. The collaboration brings together Amprion's expertise in detecting disease-specific misfo...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR). The IVDR represents one of the world’s most rigorous regulatory frameworks for in vitro diagnostic medical devices, replacing the outgoing In Vitro Diagnostic Medical Devices Directive (IVDD). To obtain certification, the Signatera platf...

CAMBRIDGE, England--(BUSINESS WIRE)--Alchemab Therapeutics has secured £25m/$34m from the British Business Bank – the Bank’s largest investment in a life sciences company to date....

VANCOUVER, British Columbia e TORONTO--(BUSINESS WIRE)--STEMCELL Technologies e il Centre for Commercialization of Regenerative Medicine (CCRM) oggi ha annunciato una collaborazione per ampliare l'accesso a materiali di partenza di alta qualità derivati da cellule staminali pluripotenti indotte umane (iPSC), offrendo agli sviluppatori di terapie cellulari di tutto il mondo un percorso più rapido e meno rischioso dalla ricerca alla clinica. Il testo originale del presente annuncio, redatto nella...

VANCOUVER, Brits-Columbia & TORONTO--(BUSINESS WIRE)--STEMCELL Technologies en het Centre for Commercialization of Regenerative Medicine (CCRM) hebben vandaag een samenwerking aangekondigd om de toegang tot hoogwaardig uitgangsmateriaal in de vorm van menselijke geïnduceerde pluripotente stamcellen (iPSC’s) te vergroten. Dit geeft ontwikkelaars van celtherapieën wereldwijd een snellere en minder risicovolle oplossing van onderzoek naar de klinische praktijk. Deze bekendmaking is officieel gelde...